GenVec Announces Third Quarter 2009 Results Conference Call

GAITHERSBURG, Md., Oct. 28 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq:
GNVC) announced that it will release financial results for the third quarter
ended September 30, 2009 on Thursday, November 5, 2009 after market close.
GenVec will hold a conference call at 10:00 a.m. EST on Friday, November 6,
2009 to discuss the company's third quarter results.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )

To listen to the live conference call, please dial 888-679-8040 (U.S. or
Canada) or 617-213-4851 (international) and use access code 35178683.
Participants may pre-register for the call anytime at:
https://www.theconferencingservice.com/prereg/key.process?key=PPCBK3H6R.

Pre-registrants will be issued a PIN number to use when dialing into the live
call, which will provide quick access to the conference. An audio replay of
the conference call will be available starting at 1:00 p.m. on November 6,
2009 through November 12, 2009. To listen to the audio replay, dial
888-286-8010 (U.S. or Canada) or 617-801-6888 (international) and use access
code 28987203.

A live webcast of the conference call will be available on the Company's
website and will be archived for 30 days. To access the webcast or the replay,
go to www.genvec.com, click on "Investor Relations," and click on "Webcasts
and Data."

About GenVec
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs
and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal
clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also
been and is currently being evaluated for its potential use in the treatment
of several other cancers, including esophageal cancer, rectal cancer, and head
and neck cancer. GenVec also uses its proprietary adenovector technology to
develop vaccines for infectious diseases including HIV, malaria,
foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2.
Additional information about GenVec is available at www.genvec.com and in the
company's various filings with the Securities and Exchange Commission.

Investor Contact: Media Contact:
GenVec, Inc. Tiberend Strategic Advisors, Inc.
Danielle M. DiPirro Andrew Mielach
(301) 944-1877 (212) 827-0020
ddipirro@genvec.com amielach@tiberendstrategicadvisors.com

SOURCE GenVec, Inc.

Investor, Danielle M. DiPirro of GenVec, Inc., +1-301-944-1877,
ddipirro@genvec.com; or Media, Andrew Mielach of Tiberend Strategic Advisors,
Inc., +1-212-827-0020, amielach@tiberendstrategicadvisors.com